119 results on '"Obermannova, R."'
Search Results
2. Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey
3. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
4. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
5. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
6. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial
7. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective
8. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
9. A wind of change in upper gastrointestinal cancers: updates from ESMO 2023
10. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
11. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
12. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
13. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
14. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
15. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
16. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
17. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
18. Isatuximab plus atezolizumab in patients with advanced solid tumors:results from a phase I/II, open-label, multicenter study
19. PD-033 Right-sided colon cancer is associated with increased frequency of KRAS mutation and with a poor outcome in patients with metastatic disease treated in the first line with bevacizumab and chemotherapy
20. PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial
21. 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
22. 1742P Gender differences in incidence trends of early-onset GI cancer: The European perspective
23. 722TiP CLAUDIO-01: A multicentric phase I/II trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care (SoC) in patients with gastric, gastroesophageal junction(GEJ), and pancreatic adenocarcinoma
24. 1579P Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
25. P-376 CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
26. O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
27. Reply to the Letter to the Editor ‘Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to “Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”)’ by Cellini et al.
28. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
29. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer
30. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
31. Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
32. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma
33. [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors]
34. Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC (ASCEND-8)
35. Circulating regulatory T-cells and the clinical outcome of VEGF-targeted treatment of metastatic colorectal cancer patients: focused on KRAS status and primary tumour sidedness
36. Analysis of angiogenesis biomarkers for ramucirumab (RAM) efficacy in patients with metastatic colorectal cancer (mCRC) from RAISE, a global, randomized, double-blind, Phase 3 study
37. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.
38. 144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
39. The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors
40. 168O Right-sided versus left-sided primary tumor location in patients with KRASmut metastatic colorectal cancer (mCRC) treated with 1st-line anti-VEGF plus chemotherapy (CTx) - Data from the National Czech Registry
41. Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer
42. LBA59 - Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC (ASCEND-8)
43. 2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer
44. 2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
45. P-066 S-1 in combination with epirubicin and oxaliplatin (EOS) in Caucasian patients (pts) with advanced or metastatic gastric cancer (AGC): Results of a phase I study
46. O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
47. OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC
48. 555P - Analysis of angiogenesis biomarkers for ramucirumab (RAM) efficacy in patients with metastatic colorectal cancer (mCRC) from RAISE, a global, randomized, double-blind, Phase 3 study
49. Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study
50. D04 - Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.